HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1904 SKF-34288 hydrochloride Apr 14 2024
E1036 BMS-986278 Apr 14 2024
S9716 H3B-8800 Apr 10 2024
E1597 RMC-6236 Apr 10 2024
E1880 OTUB2-IN-1 Apr 10 2024
E1903 SLU-PP-332 Apr 10 2024
E1876 GTS-21 dihydrochloride Apr 10 2024
E1924 TI17 Apr 10 2024
E1710 LY2780301 Apr 08 2024
E1849 TL12-186 Apr 08 2024
S8267 RapaLink-1 RapaLink-1, a third-generation bivalent inhibitor of mTOR, combines Rapamycin with MLN0128 using an inert chemical linker. It demonstrates efficacy against resistant mutants of malignant brain tumors and inhibits cancer cell progression by binding to mesenchymal markers. Apr 06 2024
E1653 CCT241533 hydrochloride CCT241533 hydrochloride is an ATP competitive, potent, and selective inhibitor of CHK2 with an IC50 of 3 nM and a Ki of 1.16 nM and shows minimal cross-reactivity against a panel of kinases. CCT241533 inhibits CHK2 activity in human tumor cell lines when subjected to DNA damage. Apr 06 2024
E1905 Nalidixic acid sodium salt Nalidixic acid sodium salt is an inhibitor of bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA supercoiling during replication, making it an effective quinolone antibiotic against both gram-positive and gram-negative bacteria. Apr 06 2024
A2160 Anti-rat Kappa Immunoglobulin Light Chain-InVivo Anti-rat Kappa Immunoglobulin Light Chain-InVivo reacts with the kappa chain of the rat immunoglobulin light chain. The κ chain is one of two types of polypeptide subunits which make up the immunoglobulin light chain. Apr 03 2024
A2161 Anti-mouse ICOSL (CD275)-InVivo Anti-mouse ICOSL (CD275)-InVivo reacts with mouse ICOSL (inducible T cell co-stimulator ligand) also known as CD275, B7RP-1, and B7-H2. ICOSL is a 40 kDa immune checkpoint protein belonging to the Ig receptor superfamily. Apr 03 2024
E1781 Biricodar Biricodar(VX-710) is a modulator of P-glycoprotein and MRP-1 with minimal in vivo toxicity. It enhances the effectiveness of various antibiotics against numerous gram-positive pathogens and exhibits potent chemosensitizing properties in cells resistant to multiple drugs. Mar 31 2024
E1554 Tefinostat(CHR-2845) Tefinostat(CHR-2845) is a monocyte/macrophage-targeted inhibitor of pan-histone deacetylase (HDAC). Tefinostat undergoes cleavage mediated by the intracellular esterase human carboxylesterase-1 (hCE-1) to yield the active acid CHR-2847. In vitro studies reveal a specific heightened sensitivity of monocytoid leukemias to tefinostat. Mar 27 2024
E1783 Conteltinib(CT-707) Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay. Mar 26 2024
E1114 Ifebemtinib Ifebemtinib(IN10018, BI853520) is a highly selective, potent inhibitor of focal adhesion kinase (FAK), with an IC50 of 1 nM for inhibiting FAK autophosphorylation. It also inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively, inhibiting spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. IN10018 exhibits anti-tumor activity in vitro and in vivo. Mar 25 2024
S9861 PY-60 PY-60 is a small-molecule activator of the transcriptional coactivator Yes-associated protein (YAP) with EC50 of 1.6 µM, which acts by inhibiting a central scaffolding protein in the Hippo pathway, Annexin A2. It promotes the regenerative repair of cutaneous wounds in pig and human models. Mar 24 2024
E1356 BI-0474 BI-0474 is a potent inhibitor of KRASG12C with an IC50 value of 7.0 nM. It inhibits GDP-KRAS::SOS1 protein-protein interactions. It exhibits anti-proliferative and anti-tumour activity and can be used in cancer research. Mar 24 2024
E1165 JAB-3068 JAB-3068 (SHP2-IN-6) is a potent allosteric inhibitor of SHP2. JAB-3068 enhances the anti-tumor activity of CD8+ T cells and can be used in combination to address non-responsive tumors alongside PD-1/PD-L1 antibodies. Mar 20 2024
E1768 MEDICA16 MEDICA16 is an inhibitor of ATP-citrate lyase and also acts as an agonist of G protein-coupled receptor 40 (GPR40). It functions to blunt the development of insulin resistance in the JCR:LA-cp rat as well as it is a potent triacylglycerol-lowering agent. Mar 14 2024
S9734 Bomedemstat Bomedemstat(IMG-7289) is an orally active and irreversible inhibitor of LSD1(lysine-specific demethylase 1). Bomedemstat exhibits the ability to enhance methylation levels of H3K4 and H3K9, subsequently leading to modifications in gene expression. Bomedemstat demonstrates anti-cancer properties by restraining cancer cell proliferation and prompting apoptosis. Mar 12 2024
E1341 Cerivastatin sodium Cerivastatin sodium, a sodium salt of cerivastatin, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase with Ki of 1.3 nM. It is also a synthetic, enantiomerically pure, pyridine derivative that effectively reduces serum cholesterol levels at microgram doses. Mar 12 2024
E1694 Sardomozide dihydrochloride Sardomozide dihydrochloride (CGP 48664A) is a potent inhibitor of S-adenosylmethionine decarboxylase (SAMDC) with an IC50 of 5 nM. It is also a potent inhibitor of polyamine oxidase and exhibits with broad spectrum antiproliferative and antitumor activity. Mar 07 2024
S7972 Litronesib Litronesib (LY2523355) is a selective allosteric inhibitor of the human mitosis-specific kinesin Eg5. LY2523355 also exhibits highly schedule-dependent, broad-spectrum anticancer activity against tumor models and causes mitotic arrest and apoptosis in cancer cells. Mar 07 2024
E4583 Sodium selenite Sodium selenite is a licensed selenium-containing product and is widely used in medicine, veterinary, and agriculture. It has the potential to cause cell death by an independent pathway of mitochondrial apoptosis, endoplasmic reticulum stress , autophagy, or necrosis. Sodium selenite is used as potential adjuvant therapy for COVID-19. Mar 06 2024
E1754 BRD7389 BRD7389 is an inhibitor of RSK family kinases with IC50 of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 also increases β-cell–specific gene expression in primary human islet cells.  Mar 06 2024
A2159 Anti-mouse CSF1R (CD115)-InVivo Anti-mouse CSF1R (CD115)-InVivo reacts with mouse colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115. CSF1R is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family. Mar 03 2024
E1722 Acetalax(Oxyphenisatin acetate) Oxyphenisatin acetate is the pro-drug of oxyphenisatin. It has antiproliferative activity and also used to be a laxative. Mar 03 2024
E1352 Butyzamide Butyzamide is a non-peptidyl thrombopoietin receptor, activator of Mpl . It also augments the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. It has potential for treatment of thrombocytopenia. Mar 03 2024
A2158 Anti-mouse Ly6G-InVivo Anti-mouse Ly6G-InVivo reacts with mouse Ly6G. Ly6G is a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Mar 01 2024
E2504 Toyocamycin Toyocamycin(Vengicide), an adenosine analog, acts as an inhibitor of XBP1. Toyocamycin is also a specific inhibitor of CDK9 with an IC50 value of 79 nM. Feb 26 2024
E1787 SN-001 SN-001 is a potent inhibitor of STING that specifically inhibits STING activation and STING-dependent signaling. SN-011 significantly decreases inflammatory cytokine production and osteoclast formation in vivo. Feb 26 2024
E1796 Dimethindene maleate Dimethindene maleate is a selective antagonist of histamine H1 and exhibits antihistamine effects. It suppresses the cromakalim-induced/glibenclamide-sensitive K+ currents in a concentration-dependent and reversible manner. Feb 26 2024
E1698 EN460 EN460 is a small-molecule inhibitor of endoplasmic reticulum oxidation 1(ERO1), which is specific for the reduced active form of ERO1α and prevents re-oxidation. It also protects cells from erastin-induced ferroptosis. Feb 26 2024
E1670 MKI-1 MKI-1(MASTL Kinase Inhibitor-1) is an small-molecule inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 9.9 μM in kinase assay. It also exerts antitumor and radiosensitizer activities through PP2A-mediated c-Myc inhibition in breast cancer models. Feb 26 2024
E1614 OUL232 OUL232 (Compound 27) is an potent inhibitor of mono-ADP-ribosylation (mono-ARTs) PARP10 with IC50 of 7.8 nM. It also inhibits PARP7, PARP11, PARP12, PARP14, and PARP15 at nM potencies. Feb 26 2024
A2150 Polyclonal Armenian hamster IgG-InVivo Polyclonal Armenian hamster IgG-InVivo is purified from Armenian hamster serum. It is ideal for use as a non-reactive control IgG for Armenian hamster antibodies in most in vivo and in vitro applications. Feb 21 2024
A2151 Anti-mouse IL-10R (CD210)-InVivo Anti-mouse IL-10R (CD210)-InVivo reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages. Feb 21 2024
A2152 Anti-mouse IFNγ (XMG1.2)-InVivo Anti-mouse IFNγ (XMG1.2)-InVivo reacts with mouse IFNγ (interferon gamma) a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. Feb 21 2024
A2153 Anti-mouse IL-2 (S4B6-1)-InVivo Anti-mouse IL-2 (S4B6-1)-InVivo reacts with mouse IL-2, a 17 kDa cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation. Feb 21 2024
A2154 Anti-mouse CD86 (B7-2)-InVivo Anti-mouse CD86 (B7-2)-InVivo reacts with mouse CD86 also known as B7-2. CD86 is an 80 kDa Ig superfamily member. Feb 21 2024
A2155 Anti-mouse F4/80-InVivo Anti-mouse F4/80-InVivo reacts with mouse F4/80 also known as EMR1. F4/80 is a 160 kDa membrane glycoprotein belonging to the EGF-TM7 family. Feb 21 2024
A2156 Anti-human PD-L1 (B7-H1)-InVivo Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. Feb 21 2024
A2157 Anti-mouse IL-6R-InVivo Anti-mouse IL-6R-InVivo reacts with the mouse IL-6 receptor α chain also known as CD126. CD126 is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily. Feb 21 2024
E1163 MS177 MS177 is an EZH2-targeting PRTOAC degrader and a potent inhibitor of enzymatic EZH2, that effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukemia cell growth inhibition, apoptosis, and cell cycle progression arrest. Feb 21 2024
E4578 Trilaciclib dihydrochloride Trilaciclib dihydrochloride(G1T28 dihydrochloride) is a potent inhibitor of CDK4/cyclin D1 and CDK6/cyclin D3 with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride regulates cell proliferation and protects against chemotherapy toxicity in murine and canine bone marrow cells. Feb 06 2024
A2141 Anti-mouse Ter-119-InVivo Anti-mouse Ter-119-InVivo reacts with mouse Ter-119, a 52 kDa glycophorin A-associated protein that is expressed by erythroid cells from the early proerythroblast stage to mature erythrocytes. Anti-mouse Ter-119-InVivo is commonly used for identifying erythrocytes and cells in the erythroid lineage. Feb 05 2024
A2142 Anti-mouse/rat IL-1β-InVivo Anti-mouse/rat IL-1β-InVivo reacts with precursor and mature secreted forms of mouse and rat IL-1β a 17 kDa pro-inflammatory cytokine produced primarily by monocytes. Feb 05 2024
A2143 Anti-mouse 4-1BB (CD137)-InVivo Anti-mouse 4-1BB (CD137)-InVivo reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137. Feb 05 2024
A2144 Anti-mouse TIGIT-InVivo Anti-mouse TIGIT-InVivo reacts with mouse TIGIT (T cell immunoreceptor with Ig and ITIM domains). TIGIT is a 26 kDa, type I transmembrane protein and a member of the poliovirus receptor (PVR) family. Feb 05 2024
A2145 Mouse IgG2b isotype control-InVivo Mouse IgG2b isotype control-InVivo is ideal for use as a non-reactive isotype-matched control for mouse IgG2b antibodies in most in vivo and in vitro applications. Feb 05 2024
A2146 Anti-LCMV nucleoprotein-InVivo Anti-LCMV nucleoprotein-InVivo reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP), a 63 kDa structural protein. Feb 05 2024
A2147 Anti-mouse CXCR3 (CD183)-InVivo Anti-mouse CXCR3 (CD183)-InVivo reacts with mouse CXCR3 also known as CD183, a 38 kDa chemokine receptor for CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC). Feb 05 2024
A2148 Anti-mouse GM-CSF-InVivo Anti-mouse GM-CSF-InVivo reacts with mouse granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony stimulating factor 2 (CSF2). Feb 05 2024
A2149 Anti-mouse CD19-InVivo Anti-mouse CD19-InVivo reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. Feb 05 2024
E1287 SB 204990 SB-204990, a γ-lactone prodrug of SB-201076, is a potent and specific inhibitor of ATP citrate lyase (ACLY). SB 204990 potently limits SARS-CoV-2 replication in vivo. Feb 04 2024
E1721 TJ-M2010-5 TJ-M2010-5 is a small molecule inhibitor of MyD88 that selectively binds to the Toll/Interleukin-1 receptor (TIR) domain of MyD88, disrupting its homodimerization and subsequently inhibiting the Toll-like receptor (TLR)/MyD88 signaling pathway. TJ-M2010-5 exhibits an anti-hepatic fibrosis effect with the potential to treat liver fibrosis. Feb 04 2024
E1713 FL118 FL118(10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin analog, is a potent and orally active inhibitor of Survivin. FL118 also selectively and independently inhibits three additional cancer-associated survival genes Mcl-1, XIAP, and cIAP2 in a p53 status-independent manner. FL118 displays potent antitumor activity and can be used in cancer research. Feb 04 2024
E1655 KT 474 KT-474 (SAR444656) is a selective small-molecule degrader of IRAK4 in development for the treatment of TLR/IL-1R–driven autoimmune diseases. KT-474 potently downregulates R848 (TLR7/8) and lipopolysaccharide (LPS)-induced IL-6 and IL-8 production in peripheral blood mononuclear cells (PBMCs). Feb 01 2024
E1627 BMS493 BMS493 is an inverse agonist of pan retinoic acid receptor (RAR). It increases nuclear corepressor interaction with RARs and can be used as an inhibitor for the dietary and pharmacologic manipulation of retinoic acid (RA) activity in vivo and in vitro. Feb 01 2024
E1685 D609 D609 is a selective, competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC) with a Ki of 6.4 μM. It is an antioxidative protector and has antiviral and anti-inflammatory activity and also inhibits angiogenesis by preventing the synthesis of basement membrane (BM). Feb 01 2024
E1748 HG6-64-1 HG6-64-1 (HMSL 10017-101-1) is a highly potent and selective inhibitor of B-Raf with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. Feb 01 2024
E1874 Erastin2 Erastin2 is an inducer of ferroptosis. It also selectively inhibits xc(-) cystine/glutamate transporter. It induces ferroptosis in HT-1080, T98G, and A549 cells with the potential to treat neurodegenerative diseases. Feb 01 2024
E1520 NSC 663284 NSC 663284(DA-3003-10) is a potent, cell-permeable, and irreversible dual specificity phosphatase inhibitor of Cdc25, and exhibits an IC50 of 0.21 μM for Cdc25B2 and is 20 and 450-fold highly selective against Cdc25B2. NSC 663284 also inhibits NSD2 with an IC50 of 170 nM via a direct interaction with the catalytic SET domain. Jan 30 2024
E1750 XST-14 XST-14 is a potent, competitive, and highly selective inhibitor of ULK1 and exhibits an IC50 of 26.6 nM in an in vitro ULK1 kinase activity assay, respectively. XST-14 reduces the phosphorylation of the ULK1 downstream substrate and induces autophagy inhibition. It exhibits antitumor effects. Jan 30 2024
E1832 ZK53 ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP). It exhibits an EC50 of 1.37 μM for α-casein hydrolysis by HsClpP. ZK53 treatment allosterically activates HsClpP to uncontrollably degrade the essential mitochondrial proteins and is inactive toward bacterial ClpP proteins. Jan 30 2024
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both. Jan 24 2024
E1749 limertinib limertinib (ASK120067) is an irreversible third-generation inhibitor of EGFRT790M with IC50 of 0.3 nM, with selectivity over EGFRWT having IC50 of 6.0 nM. It exhibits potent anti-proliferation activity in non-small cell lung cancer (NSCLC) tumor cells. Jan 23 2024
E4449 AG 825 AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells. Jan 22 2024
E1810 dCeMM1 dCeMM1 is a degrader of RBM39. dCeMM1 functions by altering the activity of the CRL4DCAF15 ligase, and also decreases RBM39 expression levels in wild-type KBM7 cells. Jan 22 2024
E1752 JNJ-42226314 JNJ-42226314 is a potent, selective, and reversible noncovalent inhibitor of monoacylglycerol lipase (MAGL). It enhances the expression of endocannabinoid 2-arachidonoylglycerol (2-AG) and exhibits antinociceptive efficacy in models of neuropathic and inflammatory pain. Jan 22 2024
E4453 Cathepsin G Inhibitor I Cathepsin G Inhibitor I exhibits reversible, competitive cathepsin G inhibition with IC50 and Ki values of 53 nM and 63 nM respectively. It can be used in antigen-processing studies and for modulation of T cell response in situ and in vivo. Jan 22 2024
E1711 FHT-1015 FHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo. Jan 21 2024
E1634 CH6953755 CH6953755 is a potent, orally active, and selective inhibitor of YES1 kinase with an IC50 of 1.8 nM. CH6953755 demonstrates antitumor activity against YES1 gene-amplified cancers. Jan 21 2024
S6392 SHIN1(RZ-2994) SHIN1 (RZ-2994) is an inhibitor of SHMT1/2 (human serine hydroxymethyltransferase 1 and 2) with IC50 values of 5 and 13 nM, respectively, in in vitro assay. SHIN1 hinders cell growth by gradually reducing purine levels. Jan 21 2024
E4580 Sovleplenib Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL). Jan 17 2024
E1769 Merbarone Merbarone(NSC 336628) is a catalytic inhibitor of topoisomerase II with IC50 of 120 μM, with anti-proliferative activity against human cancer cells. Merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage. Jan 17 2024
E1604 Vevorisertib trihydrochloride Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) is a selective, allosteric inhibitor of pan-AKT and AKT1-E17K mutant with Kd values of 1.2 nM and 8.6 nM, respectively. It also has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively and can be used for the research of cancer. Jan 16 2024
A3176 Human IgG2sa isotype control Human IgG2sa isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG2sa antibody. Jan 15 2024
E1667 LY2880070 LY2880070 is an orally active inhibitor of CHK1. LY2880070 can be used as an anticancer agent and shows promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when used in combination with DNA-damaging agents. Jan 10 2024
E1812 N6F11 N6F11 is an inducer of ferroptosis. N6F11 is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation. Jan 10 2024
E1739 MST-312 MST-312(Telomerase Inhibitor IX) is an inhibitor of telomerase. MST-312 is a chemically modified derivative of green tea epigallocatechin gallate (EGCG). MST-312 exhibits high chemical stability, lowers the effective dose in the induction of telomere shortening, and lowers drug resistance. MST-312 can be used for the research of cancer. MST-312 can also be used as a promising strategy in the treatment of multiple myeloma (MM). Jan 10 2024
E1658 PRT543 PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM. Jan 09 2024
E1744 UNC5293 UNC5293 is a potent, highly selective, orally available inhibitor of MER receptor tyrosine kinase (MERTK) with IC50 of 0.9 nM and Ki 0.19 nM. Jan 09 2024
E1742 Reversan Reversan (CBLC4H10) is a selective and nontoxic inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp), with the potential to treat neuroblastoma and other MRP1-overexpressing drug-refractory tumors. Jan 09 2024
E1723 NSC16168 NSC16168 is a specific inhibitor of ERCC1-XPF, and exhibits an IC50 value of 0.42 μM in a high throughput screen (HTS) assay, respectively. NSC16168 inhibits DNA repair and potentiates cisplatin efficacy in cancer. Jan 09 2024
E1746 Protokylol hydrochloride Protokylol hydrochloride(Caytine hydrochloride, JB-251 hydrochloride) is a salt form of protokylol and is an agonist of β-adrenergic receptor. Protokylol hydrochloride is also used as a bronchodilator. Jan 07 2024
E1727 Pimicotinib Pimicotinib (ABSK021) is an orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R). It enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells having potential immunomodulatory and antineoplastic activities. Jan 07 2024
E1564 BI-2493 BI-2493, a structural analogue of BI-2865, is a highly selective inhibitor of pan-KRAS. BI-2493 attenuates tumor growth and can be used for cancer research. Jan 07 2024
E1620 Fluorofurimazine Fluorofurimazine is a novel furimazine analogue, with increased aqueous solubility enabling higher signal emission than furimazine for bioluminescence imaging. Fluorofurimazine enables higher substrate loading and improved optical imaging sensitivity in in-vivo. Jan 04 2024
A3175 Blinatumomab (Anti-CD3 & CD19) Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts. Jan 03 2024
E1435 Tinengotinib Tinengotinib (TT-00420) is a novel multiple kinase inhibitor that strongly inhibits Aurora A/B with IC50 values of 1.2/3.3 nM respectively. It also exhibits potent inhibitory activity on FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R and can be used to treat several prominent signaling pathways in triple-negative breast cancer(TNBC). Jan 01 2024
E1649 Exarafenib Exarafenib(KIN-002787, KIN-2787, RAF/KIN_2787) is an orally-available, selective inhibitor of pan-RAF. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. KIN-2787 exhibits low nanomolar to picomolar potency against RAF1, BRAF, and ARAF with an IC50 of 0.06-3.46 nM with minimal activity towards non-RAF kinases. Dec 28 2023
E1708 Solutol HS-15 Solutol HS-15(Polyethylene glycol 12-hydroxystearate) is a Macrogol 15 hydroxy stearate, which improves permeability by disrupting the membrane structure/fluidity change. Dec 27 2023
S9463 Demecarium Bromide Demecarium Bromide, an anticholinesterase, is an inhibitor of monoamine oxidase (MAO). It induces long-term miosis and decreases intraocular pressure (IOP) in normotensive eyes of Beagles and of eyes of Beagles with inherited glaucoma. Dec 26 2023
E1538 PRGL493 PRGL493 is a potent and selective inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4). PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research. Dec 26 2023
E1775 2,4-Thiazolidinedione 2,4-Thiazolidinedione (Thiazolidinedione), an insulin sensitizer, is a specific agonist of peroxisome proliferator-activated receptor (PPAR)γ. Thiazolidinedione treatment corrects impaired muscle insulin action in vivo. Dec 26 2023
E1773 Fasoracetam (NS 105) Fasoracetam (NS 105) is a metabotropic glutamate receptor activator with a potential to treat vascular dementia. Dec 26 2023
E1714 B022 B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor with a Ki of 4.2 nM. B022 protects liver from toxin-induced inflammation, oxidative stress, and injury. Dec 26 2023
E1734 OD36 OD36 is an inhibitor of RIPK2 with an IC50 value of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. Dec 24 2023
E2983 PF-04957325 PF-04957325 is a highly potent and selective inhibitor of PDE8, with IC50 values of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively. PF-04957325 greatly potentiates steroidogenesis in wild type adrenal cells. Dec 20 2023
E1618 TC-S 7009 TC-S 7009 is a potent and selective inhibitor of HIF-2α with a Kd value of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α. It disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression. Dec 20 2023
S2520 CD437(AHPN) CD437(AHPN), a synthetic retinoid, is a selective Retinoic acid Receptor γ ( RARγ) agonist. It exhibits an antiproliferative effect and induces apoptosis via activation of AP-1 in vitro. Dec 18 2023
E1780 Alexidine dihydrochloride Alexidine dihydrochloride, a dibiguanide compound, is an effective and selective inhibitor of protein tyrosine phosphatases localized to mitochondrion 1 (PTPMT1) with an IC50 of 1.08 μM in vitro. It has the potential to treat type II diabetes. Dec 18 2023
E1605 Avotaciclib trihydrochloride Avotaciclib trihydrochloride(BEY1107 trihydrochloride) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). It can be used for the research of locally advanced or metastatic pancreatic cancer. Dec 17 2023
E1678 SPOP-i-6lc SPOP-i-6lc is a selective speckle-type POZ protein (SPOP) E3 ubiquitin ligase inhibitor with IC50 of 2.1 μM and 3.5 μM, in A498 and OS-RC-2 cell lines, respectively. In vitro, It suppresses viability and proliferation of A498 and OS-RC-2 kidney cancer cell lines. Dec 17 2023
E1743 VX-561(CTP-656, Deutivacaftor) VX-561 (Ivacaftor-D9, CTP-656, Deutivacaftor), a deuterated ivacaftor analog, is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE cells. Dec 17 2023
A3174 Mosunetuzumab (Anti-CD20 & CD3e) Mosunetuzumab (Anti-CD20 & CD3e) is expressed from CHO. The heavy chain type is IgG1, and the light chain type is hukappa. MW: 146.72 kDa. Dec 14 2023
E1028 POMHEX POMHEX, is a potent ENO2 -specific inhibitor of enolase and a racemic mixture, a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX. It is also glycolysis inhibitor and can be used for the research of cancer. Dec 13 2023
E1203 Sirpiglenastat Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities. Dec 13 2023
S8091 25-Hydroxycholesterol 25-Hydroxycholesterol is a side-chain oxysterol and a selective suppressor of IgA production by B cells with an EC50≈65 nM. It affects the immune system and has a key role in the pathogenesis of atherosclerosis. Dec 12 2023
E1409 Zidesamtinib Zidesamtinib (NVL-520) is a potent brain-penetrating inhibitor of ROS1 tyrosine kinase with IC50 of 0.7 nM for wild-type ROS1 . It acts as a potential antineoplastic agent and can be used for the research of cancer. Dec 11 2023
S8395 INDY INDY, a benzothiazole derivative is a potent and ATP-competitive inhibitor of Dyrk1A and Dyrk1B with an IC50 value of 0.24 μM and Ki value of 0.18 μM, respectively. INDY diminishes the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells. Dec 11 2023
E1636 MV1035 MV1035, an inhibitor of ALKBH5 significantly reduces GBM U87-MG cell migration and invasiveness through inhibition of the RNA demethylase ALKBH5. Dec 11 2023
E1598 VT103 VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation with anti-proliferative and anti-tumor activity. It also inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation and disrupts interaction between YAP/TAZ and TEAD. Dec 07 2023
E1735 PK11007 PK11007 is a thiol-reactive anticancer agent that stabilizes p53 via selective alkylation of two surface cysteines without compromising its DNA binding. It induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels. Dec 07 2023
E1684 C1632 C1632 (Lin28-let-7 antagonist 1) is a RNA-binding protein and a potent antagonist of Lin28/pre-let-7 interaction. It inhibits Lin28A binding to pre-let-7a-2, with an IC50 of 8 μM as well as inhibits proliferation in human cancer cells. Dec 07 2023
E1512 M3541 M3541 is a potent and selective inhibitor of ATM kinase activity with an IC50 value of 0.25 nM in cell-free assays. M3541 suppresses double-strand breaks (DSB) repair, clonogenic cancer cell growth and potentiates antitumor activity of ionizing radiation in cancer cell lines. Dec 06 2023
E1638 ALKBH5 inhibitor 2 (Cpd 20m) ALKBH5 inhibitor (Cpd 20m) is a potent and selective inhibitor of RNA m6A demethylase AlkB homolog 5 ALKBH5 with IC50 of 21 nM. Dec 05 2023
A3173 Minretumomab (CC-49) Minretumomab (CC-49) is a monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab can be used in cancer and immunity research. Dec 04 2023
A2136 Anti-mouse CD40-InVivo Anti-mouse CD40-InVivo reacts with mouse CD40 also known as Bp50. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. Dec 04 2023
A2137 Anti-mouse CD8β (Lyt 3.2)-InVivo Anti-mouse CD8β (Lyt 3.2)-InVivo reacts with mouse CD8β also known as Lyt 3.2. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). Dec 04 2023
A2138 Anti-mouse IL-2-InVivo Anti-mouse IL-2-InVivo reacts with mouse IL-2, a cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation Dec 04 2023
A2140 Anti-mouse/human/rat CD47 (IAP)-InVivo Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells. Dec 04 2023
E1603 ACT001(DMAMCL) ACT001(DMAMCL, dimethylaminomicheliolide) is a PAI-1 inhibitor and exerts antitumor effects on neuroblastoma (NB) both in vitro and in vivo. It also exerts synergistic effects in combination with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway. Nov 29 2023
  • First Page
  • Last Page